Vertex Pharmaceuticals revenue outlook for cystic fibrosis treatments

Vertex Pharmaceuticals revenue outlook for cystic fibrosis treatments


Jan 8 Vertex Pharmaceuticals Inc said on Sunday that it expected full-year 2017 revenue from its Orkambi cystic fibrosis treatment of $1.1 billion to $1.3 billion and revenue from its Kalydeco treatment of $690 million to $710 million. The company provided the outlook in a news release ahead of a presentation on Monday at the annual JPMorgan healthcare conference in San Francisco.



from Biotech News